Abstract: The present invention discloses a mouse-human chimeric antibody preferably recognizes the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and the encoding sequences, wherein the monoclonal antibody having a light chain and a heavy chain. Moreover, the present invention provides humanized light and heavy chains, and the encoding sequences. The results of paired expression show that humanized antibodies also recognize the MUC1 glycopeptide epitope RPAPGS(GalNAc)TAPPAHG (SEQ ID NO.: 34) on the surface of cancer cells, and show the same specificity as the parental antibody.

Abstract: Implementations discussed and claimed herein provide systems and methods for characterizing patient tissue of a patient. In one implementation, a pathological image of the patient tissue is received. Nuclei of the plurality of cells in the pathological image are simultaneously segmented and classified using a histology-based digital staining system. The nuclei of the plurality of cells are segmented according to spatial location and classified according to cell type, thereby generating one or more groups of nuclei. Each of the one or more groups of nuclei have an identified cell type. A composition and a spatial organization of a tumor microenvironment of the patient tissue is determined based on the one or more groups of nuclei. A prognostic model for the patient is generated based on the composition and the spatial organization of the tumor microenvironment.

Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.

Abstract: Certain embodiments are directed to an inline device(s) for monitoring a fluid path.

Abstract: A method for fabricating patterns on a flexible substrate in a roll-to-roll configuration. Drops of a monomer diluted in a solvent are dispensed on a substrate, where the drops spontaneously spread and merge with one another to form a liquid resist formulation. The solvent is evaporated (e.g., blanket evaporation) from the liquid resist formulation followed by selective multi-component resist film evaporation resulting in a non-uniform and substantially continuous film on the substrate. The gap between the film on the substrate and a template is closed such that the film fills the features of the template. After cross-linking the film to polymerize the film, the template is separated from the substrate thereby leaving the polymerized film on the substrate.

Abstract: Provided herein are RNA aptamers targeting CD5L. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer.

Abstract: The present disclosure includes exosomal protein biomarkers for differential diagnosis of idiopathic pulmonary fibrosis including a five-protein signature determined using mass spectrometry-based proteiomic analysis of plasma extracellular vesicles (EVs) for differential diagnosis of idiopathic pulmonary fibrosis.

Abstract: Described herein are pharmaceutical compositions containing peptoids of general formula (I), (II), or (III) capable of reducing proliferation of cancer stem cells in a subject and methods of treatment or prophylactic administration of these pharmaceutical compositions to treat cancer. Also provided herein are method of detecting and treating cancerous cell masses by use of peptoids of general formula (I), (II), or (III).

Abstract: The present disclosure presents aerial communication systems and methods. One such system comprises an unmanned aerial vehicle platform and a communication component integrated with the unmanned aerial vehicle platform, wherein the communication component is configured to establish an Air to Air (A2A) communication channel with a remote directional antenna that is integrated with a remote unmanned aerial vehicle platform. The system further includes a computing component integrated with the unmanned aerial vehicle platform, wherein the computing component is configured to determine an optimal heading angle for transmission of communication signals from a directional antenna to the remote directional antenna in an unknown communication environment from received signal strength indicator (RSSI) information obtained from the remote directional antenna. Other systems and methods are also disclosed.

Abstract: The present disclosure relates to sealed isocyanate resin compositions. The resin compositions may be used for additive manufacturing. One embodiment of the invention includes a photopolymerizable resin for additive manufacturing, the resin comprising: a blocked isocyanate; at least one monomer or oligomer; and a multifunctional nucleophile.

Abstract: The present disclosure addresses IBD from the standpoint of inhibiting or ablating pathogenic mucosal stem cells cloned from defined regions of disease in the gastrointestinal tract. In the case of Crohn's disease, for example, isolation of those stem cells according to the methods of the present disclosure reveals a pattern of inflammatory gene expression in stem cells from the terminal ileum and colon that is epigenetically maintained despite months of continuous cultivation in the absence of immune or stromal cells, or of intestinal microbes. Superimposed on this distributed inflammatory phenotype is a differentiation defect that profoundly and specifically alters the mucosal barrier properties of the terminal ileum. The co-existence of diseased and normal stem cells within the same endoscopic biopsies of Crohn's disease patients implicates an epigenetically enforced heterogeneity among mucosal stem cells in the dynamics of this condition.

Abstract: A method and system for generating a voxel-based quadratic penalty model for automatic intensity modulated radiation therapy (IMRT) treatment planning are disclosed herein. A computing system generates an initial assignment of threshold values to a penalty function for IMRT treatment planning. The computing system receives an update to a dose value associated with the IMRT treatment planning. The computing system dynamically updates the threshold values based on the updated dose value. The computing system continues to iterate the threshold values based on further updated dose values.

Abstract: The present disclosure provides compounds of the formula: wherein the variables are defined herein. The present disclosure also provides methods of imaging Zn2+ within granules in cells, such as pancreatic ?-, ?-, and ?-cells. The present disclosure also provides methods of sorting cells comprising the use of the compounds of the present disclosure.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: Shielding enzymes are made by modifying the enzyme surface with silica precursors and then depositing silica to a desired thickness while retaining biological activity of the enzyme.

Abstract: The present disclosure is directed to antibodies that bind to DC-HIL on the surface of myeloid-derived suppressor cells, and thus antagonize the T cell suppressor function of these cells, as well as their use in diagnosing and treating cancers such as melanoma.

Abstract: This disclosure provides for engineered T cell Receptors (TCRs), cells comprising the TCRs, and methods of making and using the TCRs. The current disclosure relates to TCRs that specifically recognize gp100. Accordingly, aspects of the disclosure relate to an engineered T-cell Receptors (TCRs), nucleic acids encoding the TCRs, and cells comprising the nucleic acids and TCRs. Also provided are compositions comprising the cells, nucleic acids, or engineered TCRs of the disclosure, methods of making the cells and methods of using the embodiments of the disclosure for therapeutic treatments.

Abstract: A method of synthesizing a clopidogrel metabolite is provided. A piperidone intermediate is formed from a mandelate. An asymmetric ketone reduction of the piperidone intermediate is performed. A mercapto installation is performed on the piperidone intermediate to form a clopidogrel metabolite that includes a 4-carbon chiral center having an (R) configuration.

Abstract: Certain embodiments are directed to methods and compositions for treating obesity, diabetes, and/or cancer with a combination of ursolic acid and resveratrol.